Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00629369 · ClinicalTrials.gov registry record · NA
Duration of Second Stage of Labor Wearing a Dental Occlusion Device
A NA study, sponsored by Mercy Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
NCT00629369: Completed NA study, sponsored by Mercy Medical Center.
NCT00629369 is a NA study that has completed, run by Mercy Medical Center. The registered enrollment target is 64 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00629369, a NA study, has completed, sponsored by Mercy Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
Study Summary
Developing a method to maximize maternal expulsive effort should be of great value in reducing the number of cesarean section or instrumental deliveries. Various investigations have shown that use of an occlusal support device (OSD) increases the isometric strength of different muscle groups. The aim of our study was to investigate the role of an OSD in second stage pushing.
Interventions
- DEVICE Extra 3 mouth guard, Shock doctor mouth guard v3.0
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2007-10 |
| Est. Completion | 2007-12 |
| Phase | NA |
What the finished NCT00629369 record still lists
NCT00629369 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Extra 3 mouth guard, Shock doctor mouth guard v3.0 is the first listed.
NCT00629369 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00629369 about?
NCT00629369 is a clinical study titled "Duration of Second Stage of Labor Wearing a Dental Occlusion Device". Developing a method to maximize maternal expulsive effort should be of great value in reducing the number of cesarean section or instrumental deliveries. Various investigations have shown that use of an occlusal support device (OSD) increases the isometric strength of different muscle groups. The ai...
What is the current status of trial NCT00629369?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2007-10. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00629369?
The interventions under investigation include: Extra 3 mouth guard, Shock doctor mouth guard v3.0 (DEVICE).
Who is sponsoring clinical trial NCT00629369?
This trial is sponsored by Mercy Medical Center, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00629369's enrollment target sits among peer trials
64 1147th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia